ROCHE

Tarceva-erlonat

"Tarceva" contains Drug / Molecules called “Erlotinib”. Tarceva belongs to Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors. The medication works by interfering with the protein epidermal growth factor to prevent it from activating enzymes, cancer cells require these to multiply, grow and spread.

“Erlonat” is the generic version of "Tarceva" and both contains same drug “Erlotinib”.

Details
Specification

Indication

Tarceva is used for the treatment of advance or metastatic Non-Small Cell Lung cancer pancreatic cancer and several other types of cancer.

Note

SIDE EFFECTS :

Rash occurs in the majority of patients.
Diarrhea, Loss of appetite, Fatigue, Partial Hair Loss.
Rarely, ingrown hairs, such as eyelashes.

INTERACTIONS :

Cigarette smoking decreases blood levels while taking Tarceva.
Check all prescription and non-prescription medicine labels carefully since many medications contain pain relievers / fever reducers ( aspirin, NSAIDs such as ibuprofen or naproxen) which may increase your risk for stomach bleeding while taking Tarceva.
Do not start, stop, or change the dosage of any medicines without your doctor's approval.

OVERDOSE :

Do not use more than prescribed dose.
If you suspect you may have overdosed, call your healthcare provider.
Do not take extra dose to make up for the missed dose.

Precaution

Tarceva are prescription drug and should be used under proper medical guidance and advice.
Caution should be exercised in patients with history of stomach problem, liver, kidney, or heart disease during pregnancy and breastfeeding.

Updated On Oct 15, 2019 by Admin

Strength

100 mg & 150 mg

Packing

1 X 30 Tablets (Strip)

Storage

Store at room temperature

Was this page helpful?

☆ ☆ ☆ ☆ ☆

Not Upto Date Insufficient Helpful

Any suggestions or inputs for Shubhampharma.

Tarceva-erlonat also available as

Fast moving

NATCO PHARMA LIMITED (INDIA)

Erlonat

“Erlonat” contains the Drug / Molecule called “Erlotinib”.

Erlonat belongs to Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors. The medication works by interfering with the protein epidermal growth factor to prevent it from activating enzymes, Cancer cells require these to multiply, grow and spread.